Condition: Juvenile Idiopathic Arthritis · Sponsor: Sanofi
Primary Objective: To describe the pharmacokinetic (PK) profile of sarilumab in patients aged 1-17 years with Systemic Juvenile Idiopathic Arthritis (sJIA) in order to identify the dose and regimen for adequate treatment of this population. Secondary Objective: To describe the pharmacodynamics (PD) profile, the efficacy, and the long term safety of sarilumab in patients with sJIA.
This description comes directly from the study's public registry record.
Trial Transparency email recommended (Toll free for US & Canada) · 800-633-1610 · Contact-Us@sanofi.com
Always discuss trial participation with your own doctor first.
| Investigational Site Number : 0320004 | San Miguel de Tucumán, Tucumán Province, Argentina | Recruiting |
| Investigational Site Number : 0320005 | Buenos Aires, Argentina | Recruiting |
| Investigational Site Number : 1240110 | Calgary, Alberta, Canada | Recruiting |
| Investigational Site Number : 2460040 | Helsinki, Finland | Recruiting |
| Investigational Site Number : 2500041 | Bron, France | Recruiting |
| Investigational Site Number : 2500042 | Montpellier, France | Recruiting |
| Investigational Site Number : 2500040 | Paris, France | Recruiting |
| Investigational Site Number : 2760064 | Berlin, Germany | Recruiting |
| Investigational Site Number : 2760065 | Berlin, Germany | Recruiting |
| Investigational Site Number : 2760062 | Hamburg, Germany | Recruiting |
| Investigational Site Number : 2760060 | Sankt Augustin, Germany | Recruiting |
| Investigational Site Number : 2760063 | Sendenhorst, Germany | Completed |
+ 20 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02991469